FDA reviews update to Pfizer vaccine for kids

Nov 16, 2009 By MATTHEW PERRONE , AP Business Writer

(AP) -- Federal health officials on Monday questioned whether to approve an updated version of Pfizer's best-selling anti-infection vaccine for children, despite company studies that failed to meet certain goals.

The Prevnar 13 vaccine reduces risk of infection by 13 varieties of pneumococcal disease, which causes ear infections, and . The new version of the vaccine protects against six more varieties of the disease.

But reviewers said that company studies failed to meet the preselected goals for three types of the disease, according to documents posted online.

The missed goals were statistical measures for vaccine response selected by the FDA. However, since no other vaccine fights the same of the disease as Prevnar, the FDA said the significance of the missed goals "may not be clear."

Dr. Emilio Emini, Pfizer's chief of vaccine research, said the missed goals were due to statistical groupings of patients in the study, not a flaw with the vaccine itself.

Pfizer's briefing documents note that the World Health Organization's vaccine guidelines say meeting the study goals in question is "desirable, but not an absolute requirement."

The FDA will ask a panel of outside vaccine experts to weigh in on the results at a meeting Wednesday. The agency is expected to make its decision on the vaccine by Dec. 30. The FDA is not required to follow the group's advice, though it usually does.

Pfizer acquired Prevnar from Wyeth, as part of a $68 billion buyout that closed last month. Prevnar's $2.7 billion in sales last year trailed only those of the antidepressant Effexor for Wyeth.

Wyeth applied for approval of Prevnar 13 in March and was granted a priority review from the FDA, which indicates the agency sees the product as a public health priority.

Pfizer has said the new vaccine will save lives in the U.S. and in developing countries.

"The public health imperative for this vaccine is clearly there," Emini said. "Pneumococcal disease is the number one cause of vaccine-preventable death in world."

New York-based is seeking FDA approval to market the vaccine for infants and young children and has tested it in more than 7,000 youngsters in 13 major studies.

Prevnar has been on the market for more than nine years and is on sale in 95 countries. More than 235 million doses have been distributed, according to the company.

The requires a series of four injections, generally given at 2, 4 and 6 months old and then between 12 and 15 months old.

Prevnar 13 also recently received a positive review from a committee of European regulators, setting the stage for approval across the European Union.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA OKs Merck tablet to reduce ragweed allergies

add to favorites email to friend print save as pdf

Related Stories

Wyeth seeking approval for advanced infant vaccine

Mar 31, 2009

(AP) -- Drugmaker Wyeth on Tuesday sought U.S. approval to sell a new version of its blockbuster infant vaccine Prevnar that protects against more strains of a bacteria that causes pneumonia and other diseases.

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

Recommended for you

Study recalculates costs of combination vaccines

14 hours ago

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

17 hours ago

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

Pyridoxine-doxylamine drug safety data lacking

Apr 16, 2014

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

brant
not rated yet Nov 16, 2009
For these vaccine studies to really be effective wouldnt you have to infect a bunch of kids to see if they get infected??

Do you think they would allow that???

I tell you what. I would never put this stuff in my kids!!! The vaccine load is high enough as it is for young developing bodies.

More news stories

Leeches help save woman's ear after pit bull mauling

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

Male monkey filmed caring for dying mate (w/ Video)

(Phys.org) —The incident was captured by Dr Bruna Bezerra and colleagues in the Atlantic Forest in the Northeast of Brazil.  Dr Bezerra is a Research Associate at the University of Bristol and a Professor ...

Scientists tether lionfish to Cayman reefs

Research done by U.S. scientists in the Cayman Islands suggests that native predators can be trained to gobble up invasive lionfish that colonize regional reefs and voraciously prey on juvenile marine creatures.